On the Swedish board Avanza there was a signature that wanted a pharagraph #6 to be added to my earlier post.
6. The post approval study in the EU will pass an interimistic report late 2011 that will be used to refine the labeling "not have been showing evident efficacy over 60 years of age. That will be explicit in that report. The report will also be used by Meda in promotion to prescriping physicians. Also, I suggest, it will be added by Meda, later, to the application for approval in the Asian markets.
The study have excellent results up til now Talley said two month ago. The patient group will be more than doubled, if refined.
7. Speaking about Meda's promotion, the current strategy is to gather groups with key opinion leaders to use Ceplene in different studies. Some of these studies gives Meda contracts on Ceplene, that will, after the whole study is conducted, give "seven figure" sales each in Euro.
Meda is indeed a professional actor here.
8. Talley followed the line for Crolibulin as was stated two years ago, phase II results that demonstrates proof of concepts will be followed by a outlicening.